{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:36:16Z","timestamp":1740137776075,"version":"3.37.3"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"08","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>\n            Introduction\u2003Current guideline suggests a switch from vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) in patients with low time in therapeutic range (TTR\u2009&lt;\u200970%). Poor international normalized ratio (INR) control may be the result of poor compliance, and might therefore be associated with subsequent DOAC intake. Therefore, this study evaluates the effect of previous TTR and other measures of INR control on DOAC nonadherence and nonpersistence, in patients who switched from VKA to DOAC.<\/jats:p><jats:p>\n            Methods\u2003A total of 437 patients who switched from VKA to DOAC between 2012 and 2019 were included using data from Certe Thrombosis Service, IADB.nl pharmacy community database University Groningen, and Statistics Netherlands. DOAC prescriptions were used to determine nonadherence and nonpersistence. INR control (i.e., TTR, time under therapeutic range [TUR], and INR variability) was assessed during the last 180 days of VKA use. Multivariable regression models were applied to determine the association between INR control and DOAC nonpersistence\/nonadherence.<\/jats:p><jats:p>\n            Results\u2003On VKA, 67.7% of the patients had a TTR below 70%. DOAC nonpersistence was 39.8% (95% confidence interval [CI]: 33.4\u201345.5%) during a median follow-up of 34.4 months (interquartile range: 19.1\u201349.2). Approximately 80% of persistent patients were DOAC-adherent. Low TTR was not associated with DOAC nonpersistence (hazard ratio: 1.14, 95% CI: 0.69\u20131.87) and DOAC nonadherence (odds ratio: 1.38, 95% CI: 0.67\u20132.84), nor were TUR and INR variability.<\/jats:p><jats:p>\n            Conclusion\u2003Previous INR control during VKA therapy is not associated with subsequent DOAC nonadherence and nonpersistence. This study suggests that INR control on VKA cannot, and therefore should not, be used for predicting DOAC adherence or persistence.<\/jats:p>","DOI":"10.1055\/a-2168-9378","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T22:53:15Z","timestamp":1694040795000},"page":"778-790","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC"],"prefix":"10.1055","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-6491","authenticated-orcid":false,"given":"Tessa","family":"Elling","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eelko","family":"Hak","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, Unit of Pharmacotherapy, Epidemiology and Economy, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens H.","family":"Bos","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, Unit of Pharmacotherapy, Epidemiology and Economy, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir Y. I. G.","family":"Tichelaar","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands"},{"name":"Certe Thrombosis Service, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nic J. G. M.","family":"Veeger","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Groningen, University Medical Centre, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11239-015-1317-0","article-title":"Guidance for the treatment of deep vein thrombosis and pulmonary embolism","volume":"41","author":"M B Streiff","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"e005969","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"13","author":"A F Ozaki","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2019-315307","article-title":"Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study","volume":"106","author":"A Banerjee","year":"2020","journal-title":"Heart"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jjcc.2021.02.007","article-title":"Current status of oral anticoagulant adherence in Japanese patients with atrial fibrillation: a claims database analysis","volume":"78","author":"N Yagi","year":"2021","journal-title":"J Cardiol"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/pds.5242","article-title":"Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study","volume":"30","author":"G D Zielinski","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"23","key":"ref7","doi-asserted-by":"crossref","first-page":"e020904","DOI":"10.1161\/JAHA.121.020904","article-title":"Direct oral anticoagulant adherence of patients with atrial fibrillation transitioned from warfarin","volume":"10","author":"K N Pundi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.036","article-title":"Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoagulation service","volume":"193","author":"A Packard","year":"2020","journal-title":"Thromb Res"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12872-017-0671-6","article-title":"Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration","volume":"17","author":"R T Borne","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"40","key":"ref10","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1093\/eurheartj\/ehab421","article-title":"Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study","volume":"42","author":"M MA Toorop","year":"2021","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2147\/CLEP.S163037","article-title":"Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: the PharmLines initiative","volume":"10","author":"R Sediq","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"F R Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","article-title":"Risk factors for complications of chronic anticoagulation. A multicenter study","volume":"118","author":"S D Fihn","year":"1993","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"e0188482","DOI":"10.1371\/journal.pone.0188482","article-title":"The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis","volume":"12","author":"A S Vestergaard","year":"2017","journal-title":"PLoS One"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2004.05348.x","article-title":"Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism","volume":"128","author":"N J Veeger","year":"2005","journal-title":"Br J Haematol"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a warfarin-treated population with atrial fibrillation","volume":"1","author":"F Bj\u00f6rck","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1538-7836.2007.02874.x","article-title":"Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants","volume":"6","author":"Y van Leeuwen","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jclinepi.2018.12.003","article-title":"A systematic review finds inconsistency in the measures used to estimate adherence and persistence to multiple cardiometabolic medications","volume":"108","author":"S D Alfian","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pds.3935","article-title":"Estimating time-varying drug adherence using electronic records: extending the proportion of days covered (PDC) method","volume":"25","author":"M J Bijlsma","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/phar.1989","article-title":"Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation","volume":"37","author":"B S Manzoor","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/rth2.12261","article-title":"Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study","volume":"4","author":"G D Zielinski","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2018.05.013","article-title":"Persistence to direct oral anticoagulants for acute venous thromboembolism","volume":"167","author":"C EA Dronkers","year":"2018","journal-title":"Thromb Res"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-019-01959-x","article-title":"Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center","volume":"49","author":"S M Patel","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/jth.15592","article-title":"Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: does low time in therapeutic range affect persistence?","volume":"20","author":"M MA Toorop","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.18060","article-title":"Oral anti-coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: a Danish nationwide cohort study","volume":"197","author":"A G Ording","year":"2022","journal-title":"Br J Haematol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"J K Schaefer","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/03007995.2020.1725743","article-title":"Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation","volume":"36","author":"D Mitrovic","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erp.13.20","article-title":"The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges","volume":"13","author":"S T Visser","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2168-9378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:57:29Z","timestamp":1730815049000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2168-9378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":31,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2168-9378","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"type":"print","value":"0340-6245"},{"type":"electronic","value":"2567-689X"}],"subject":[],"published-other":{"date-parts":[[2023,9,6]]},"published":{"date-parts":[[2023,9,6]]}}}